DK3444268T3 - Staphylococcus aureus-leukocidiner, terapeutiske sammensætninger og anvendelser deraf - Google Patents

Staphylococcus aureus-leukocidiner, terapeutiske sammensætninger og anvendelser deraf Download PDF

Info

Publication number
DK3444268T3
DK3444268T3 DK18196549.2T DK18196549T DK3444268T3 DK 3444268 T3 DK3444268 T3 DK 3444268T3 DK 18196549 T DK18196549 T DK 18196549T DK 3444268 T3 DK3444268 T3 DK 3444268T3
Authority
DK
Denmark
Prior art keywords
leucocidins
applications
staphylococcus aureus
therapeutic compositions
therapeutic
Prior art date
Application number
DK18196549.2T
Other languages
English (en)
Inventor
Victor J Torres
Ashley L Dumont
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of DK3444268T3 publication Critical patent/DK3444268T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
DK18196549.2T 2010-05-05 2011-05-05 Staphylococcus aureus-leukocidiner, terapeutiske sammensætninger og anvendelser deraf DK3444268T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33155010P 2010-05-05 2010-05-05
EP16187485.4A EP3121191B1 (en) 2010-05-05 2011-05-05 Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof

Publications (1)

Publication Number Publication Date
DK3444268T3 true DK3444268T3 (da) 2022-01-31

Family

ID=44902083

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18196549.2T DK3444268T3 (da) 2010-05-05 2011-05-05 Staphylococcus aureus-leukocidiner, terapeutiske sammensætninger og anvendelser deraf

Country Status (21)

Country Link
US (5) US9783582B2 (da)
EP (4) EP2566519B1 (da)
JP (4) JP6031029B2 (da)
KR (3) KR20190133290A (da)
CN (2) CN103025352B (da)
AU (5) AU2011247989C1 (da)
BR (1) BR112012029521A2 (da)
CA (2) CA2798355C (da)
DK (1) DK3444268T3 (da)
ES (2) ES2605476T3 (da)
HR (1) HRP20220068T1 (da)
HU (1) HUE058787T2 (da)
IL (2) IL222874B (da)
LT (1) LT3444268T (da)
MX (4) MX364642B (da)
MY (1) MY165618A (da)
PL (1) PL3444268T3 (da)
RU (2) RU2677140C1 (da)
SI (1) SI3444268T1 (da)
WO (1) WO2011140337A2 (da)
ZA (4) ZA201208455B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677140C1 (ru) * 2010-05-05 2019-01-15 Нью-Йорк Юниверсити Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение
LT3403669T (lt) * 2011-06-19 2020-10-12 New York University Staphylococcus aureus infekcijų ir giminingų būklių gydymo bei prevencijos būdai
EP2668208B1 (en) 2012-04-17 2015-06-03 ARSANIS Biosciences GmbH Cross-reactive staphylococcus aureus antibody
US9657103B2 (en) 2012-05-02 2017-05-23 New York University Methods of treating and preventing Staphylococcus aureus infections and associated conditions
KR101826538B1 (ko) * 2012-05-30 2018-02-07 현대자동차 주식회사 차량용 글래스 몰딩 부착 장치 및 그 방법
WO2014187746A2 (en) * 2013-05-21 2014-11-27 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
WO2014205127A2 (en) 2013-06-18 2014-12-24 New York University Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
JP6473746B2 (ja) * 2013-10-17 2019-02-20 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 交差反応性黄色ブドウ球菌抗体配列
MX2016007533A (es) 2013-12-09 2016-12-14 Univ New York Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
CN106132988A (zh) * 2013-12-19 2016-11-16 阿尔萨尼斯生物科学有限责任公司 抗金黄色葡萄球菌lukgh(lukab)毒素的抗体和抗体序列
JP2018517708A (ja) * 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
WO2018165089A1 (en) * 2017-03-06 2018-09-13 Vanderbilt University Human monoclonal antibodies to staphylococcus aureus lukab toxin
EP3638286A4 (en) * 2017-06-13 2021-03-10 Integrated Biotherapeutic Vaccines, Inc. IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS
KR102061735B1 (ko) * 2018-06-08 2020-01-02 대한민국(농림축산식품부 농림축산검역본부장) 황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물
WO2020023644A2 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
TW202035443A (zh) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌抗體的組合
WO2020076790A1 (en) * 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
AU2020358862A1 (en) 2019-10-02 2022-04-14 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
EP4216982A2 (en) * 2020-09-28 2023-08-02 Janssen Pharmaceuticals, Inc. Variant staphylococcusaureus luka and lukb polypeptides and vaccine compositions
JP2024512751A (ja) * 2021-04-02 2024-03-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓワクチン組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US300A (en) 1837-07-29 Machine foe spinning woolen roving
US400A (en) 1837-09-25 Mode of causing puppet valves to work lights
RU2122862C1 (ru) * 1995-12-08 1998-12-10 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
CA2404260A1 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2003303301B2 (en) 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
CN102698261A (zh) 2005-06-13 2012-10-03 葛兰素史密斯克蓝生物品公司 Panton-valentine杀白细胞素用于治疗和预防葡萄球菌感染的用途
CN100485038C (zh) * 2005-09-13 2009-05-06 四川大学华西医院 小型化抗耐药金黄色葡萄球菌多肽及其应用与制备方法
WO2007100580A2 (en) * 2006-02-22 2007-09-07 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
CN101466406B (zh) * 2006-06-12 2012-06-27 葛兰素史密斯克蓝生物品公司 α-毒素在治疗和预防葡萄球菌感染上的用途
CN101535811B (zh) 2006-10-18 2016-05-04 生物梅里埃公司 用于体外诊断产pvl金黄色葡萄球菌的方法
GB0624340D0 (en) * 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
WO2009029831A1 (en) * 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
JP2011500036A (ja) 2007-10-15 2011-01-06 ザ ユニバーシティー オブ クイーンズランド 構築物系およびその使用
CN101182350A (zh) * 2007-11-02 2008-05-21 山东省农业科学院奶牛研究中心 金黄色葡萄球菌α-溶血素及其编码序列
WO2009111177A2 (en) * 2008-03-05 2009-09-11 Mount Sinai School Of Medicine Of New York University Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy
EP2291196A4 (en) * 2008-05-12 2012-05-30 Strox Biopharmaceuticals Llc FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
JP5792621B2 (ja) 2008-09-26 2015-10-14 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
SG175092A1 (en) * 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
RU2677140C1 (ru) * 2010-05-05 2019-01-15 Нью-Йорк Юниверсити Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение

Also Published As

Publication number Publication date
JP2020055835A (ja) 2020-04-09
AU2011247989C1 (en) 2015-05-14
CA3088918A1 (en) 2011-11-10
US20190330284A1 (en) 2019-10-31
KR102050078B1 (ko) 2019-11-28
AU2016262661A1 (en) 2016-12-08
AU2016262661B2 (en) 2019-07-25
MX2012012859A (es) 2013-03-20
WO2011140337A3 (en) 2012-03-15
KR20180137612A (ko) 2018-12-27
IL222874B (en) 2020-05-31
SI3444268T1 (sl) 2022-05-31
EP3444268A1 (en) 2019-02-20
LT3444268T (lt) 2022-04-11
JP7001661B2 (ja) 2022-02-21
EP2566519A4 (en) 2014-01-15
PL3444268T3 (pl) 2022-04-19
ZA201208455B (en) 2016-07-27
ZA201802995B (en) 2020-12-23
US20130095115A1 (en) 2013-04-18
MX2019005156A (es) 2019-08-05
US20180099998A1 (en) 2018-04-12
AU2021236457A1 (en) 2021-10-14
AU2011247989A1 (en) 2012-12-06
BR112012029521A2 (pt) 2018-03-06
AU2021236457B2 (en) 2024-05-02
US20230295248A1 (en) 2023-09-21
EP3121191A1 (en) 2017-01-25
HUE058787T2 (hu) 2022-09-28
EP3121191B1 (en) 2018-09-26
MX364642B (es) 2019-05-03
US9783582B2 (en) 2017-10-10
JP2017048206A (ja) 2017-03-09
US10316067B2 (en) 2019-06-11
MX2021003906A (es) 2021-09-30
JP6253742B2 (ja) 2017-12-27
CN103025352A (zh) 2013-04-03
RU2644237C2 (ru) 2018-02-08
HRP20220068T1 (hr) 2022-04-15
WO2011140337A2 (en) 2011-11-10
ES2904314T3 (es) 2022-04-04
JP2018076324A (ja) 2018-05-17
ES2605476T3 (es) 2017-03-14
CN107286224A (zh) 2017-10-24
EP4015523A1 (en) 2022-06-22
RU2677140C1 (ru) 2019-01-15
RU2018146933A (ru) 2020-06-29
EP2566519B1 (en) 2016-09-07
JP6678634B2 (ja) 2020-04-08
JP2013531620A (ja) 2013-08-08
ZA202002470B (en) 2022-12-21
CA2798355C (en) 2020-09-15
EP3444268B1 (en) 2021-12-15
CA2798355A1 (en) 2011-11-10
KR20190133290A (ko) 2019-12-02
US20110274693A1 (en) 2011-11-10
CN103025352B (zh) 2017-07-11
AU2011247989B2 (en) 2014-11-27
AU2015200901A1 (en) 2015-03-12
AU2019222824A1 (en) 2019-09-19
RU2012152086A (ru) 2014-06-10
US8431687B2 (en) 2013-04-30
KR101933226B1 (ko) 2018-12-28
IL274109A (en) 2020-06-30
US11584782B2 (en) 2023-02-21
IL222874A0 (en) 2012-12-31
AU2015200901B2 (en) 2016-12-15
ZA201603107B (en) 2018-09-26
MY165618A (en) 2018-04-18
EP2566519A2 (en) 2013-03-13
KR20130060230A (ko) 2013-06-07
JP6031029B2 (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
ZA202002470B (en) Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
DK2925293T3 (da) Topiske tetracyclinformuleringer, fremstilling og anvendelser deraf
BR112013011844A2 (pt) composições pesticidas agrícolas
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
BR112013006293A2 (pt) arilpirrolidinas pesticidas
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
BR112015002738A2 (pt) composto , e , composição farmacêutica
DK2585437T3 (da) Thioacetatforbindelser, sammensætninger og fremgangsmåder til anvendelse heraf
DK3175711T3 (da) Parasitiske sammensætninger indeholdende multiple aktivstoffer, fremgangsmåder og anvendelser deraf
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
BR112012024023A2 (pt) Misturas pesticidas
BR112013014665A2 (pt) misturas pesticidas
BR112013010782A2 (pt) combinações pesticidas
FI20115816L (fi) Antimikrobinen ionomeerikoostumus sekä sen käyttösovellukset
BRPI1008323A2 (pt) Composições pesticidas
BR112012013182A2 (pt) composições tópicas germicidas
DK2547361T3 (da) Bakterielle vaccinekomponenter fra staphylococcus aureus og anvendelser deraf
DK2917212T3 (da) Antimikrobielle midler
BR112014028443A2 (pt) composição estéril.
BR112013013165A2 (pt) composição herbicida compreendendo flazassulfuron e nicossulfuron
BR112013009512A2 (pt) composição herbicida
DK2598175T3 (da) Radiofarmaceutiske sammensætninger
DK2563375T3 (da) Farmaceutiske sammensætninger med phosphonium-antimikrobielle midler
DK3241569T3 (da) Antimikrobiel sammensætning
DK2558132T3 (da) Antimikrobiel gel